Third microsphere cancer therapy filed for Japanese approval after govt request
This article was originally published in Scrip
Executive Summary
Nippon Kayaku is aiming to expand its already strong presence in oncology through an approval filing in Japan for NK938, an embolic bead product for the treatment of hypervascular tumours and arteriovenous malformation.